WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
diketopiperazine and particle adj3 size	196

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L8

Refine Search

Recall Text | Clear

Search History

DATE: Friday, March 07, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L8	diketopiperazine and particle adj3 size	196	L8
L7	dioxapiperazine and particle adj3 size	2	L7
L6	diketopiperazine and inhal$ and particle adj3 size	25	L6
L5	L4 and particle adj3 size	159	L5
L4	l1 and (nasal or powder)	225	L4
L3	l1 and nasal	25	L3
L2	diketopiperazine same (microparticle$ or particle$)	40	L2
L1	diketopiperazine and (microparticle$ or particle$)	309	L1

END OF SEARCH HISTORY

Aug 9 9

☐ Generate Collection

L3: Entry 8 of 25 File: USPT Dec 10, 2002

DOCUMENT-IDENTIFIER: US 6492553 B1
TITLE: Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds

Brief Summary Text (4):
Diketopiperazines are known to be ligands of neurokinin-2 receptors and neurokinin-3 receptors (Gordon, D. W.; Steele, J. Bioorg. Med. Chem. Lett., 1995, 5, 47. (b) Terrett, N. K.; Gardner, M.; Gordon, D. W.; Kobylecki, R. J.; Steele, J., Tetrahedron, 1995, 51, 8135) and are useful in the treatment of asthma, inflammation, Parkinsons disease, anxiety, psychosis, epilepsy and pain.

Brief Summary Text (17):
to produce the N-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compound. The invention is also directed to a method for cyclizing an N-[(aliphatic or aromatic)carbonyl)]-2-aminoacetamide compound to a cyclic compound selected from the group consisting of a 1,4-benzodiazepine-2,5-dione derivatives, diketopiperazine derivatives, ketopiperazine derivatives, lactam derivatives, 1,4-benzodiazapine derivatives and dihydroquinoxalinones derivative, cyclic ureas, hydantoins, as well as to the cyclized compound per se.

Brief Summary Text (95):
"Formulations suitable for nasal or inhalational administration" means formulations which are in a form suitable to be administered nasally or by inhalation to a patient. The formulation may contain a carrier, in a powder form, having a particle size, for example, in the range 1 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc.) Suitable formulations wherein the carrier is a liquid, for administration as, for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents. Inhalational therapy is readily administered by metered dose inhalers.

Brief Summary Text (99):
"Formulations suitable for systemic administration" means formulations which are in a form suitable to be administered systemically to a patient. The formulation is preferably administered by injection, including transmuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the compounds of the invention are formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included. Systemic administration also can be by transmucosal or transdermal means, or the compounds can be administered orally. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, bile salts and fusidic acid derivatives for transmucosal administration. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through use of nasal sprays, for example, or suppositories. For oral administration, the compounds are formulated into conventional oral administration forms such as capsules, tablets, and tonics.

Brief Summary Text (138):
"Solid support" is represented as "{character pullout}" and means a substrate which is inert to the reagents and reaction conditions described herein, as well as being substantially insoluble in the media used. Representative solid supports include inorganic substrates such as kieselguhr, silica gel, and controlled pore glass; organic polymers including polystyrene, including 1-2% copolystyrene divinyl benzene

(gel form) and 20-40% copolystyrene divinyl benzene (macro porous form), polypropylene, polyethylene glycol, polyacrylamide, cellulose, and the like; and composite inorganic/polymeric compositions such as polyacrylamide supported within a matrix of kieselguhr particles. See J. M. Stewart and J. D. Young, Solid-phase Peptide Synthesis, 2nd. Ed., Pierce Chemical Co. (Chicago, Ill., 1984).

Brief Summary Text (150):
One particular aspect of the present invention is directed to a method for preparing a cyclized compound selected from group of formulae consisting of 1,4-benzodiazepine-2,5-dione derivatives of general formulae (I), and (VII), diketopiperazine derivatives of general formula (II), ketopiperazine derivatives and dihydroquinoxalinone derivatives of general formula (III) and (VIII), dihydroimidazole derivatives of general formula (IV), lactam derivatives of general formula (V), 1,4-benzodiazepine-2,5-dione diketopiperazine derivatives of formula (VI), ketopiperazine derivatives of formula (XLII), cyclic urea derivatives of general formulae (L) and (LIII), and hydantoin derivatives of general formula (LV):--. ##STR6## ##STR7##

Brief Summary Text (180):
In another aspect, this invention is directed to the preparation of 1,4-benzodiazepine-2,5-dione derivatives of general formulae (I) and (VI), diketopiperazine derivatives of general formula (II), ketopiperazine derivatives and dihydroquinoxalinone derivatives of general formula (III) and (VIII), dihydroimidazole derivatives of general formula (IV), lactam derivatives of general formula (V), cyclic urea derivatives of general formulae (L) and (LIII), and hydantoin derivatives of general formula (LV), by solid phase synthesis employing the Ugi multi-component reaction (MCR) (Ugi, I., Angew. Chem. Int. Ed. Engl., 1962, 1, 8) using an isonitrile functionalized polymer resin linker (IXa) as described herein, followed by amine deprotection, cleavage from the resin and cyclization. The alkoxide and hydroxide safety-catch clipping strategy and subsequent solution phase cyclization offers similar advantages to a traceless linker (Plunkett, M. J.; Ellman, J. A. J. Org Chem. 1995, 60, 6006; Hulme, C.; Peng, J.; Morton, G.; Salvino, J. M.; Herpin, T.; Labaudiniere, R. Tetrahedron Let. 1998, 39,) in that no constant functionality derived from clipping remains at the end of the synthetic protocol.

Brief Summary Text (182):
In another aspect, this invention is directed to the preparation and use of a novel resin bound isonitrile (IXa), deployed as a novel safety catch linker (Backes, B. J., Virgilio, A. A., Ellman, J. A. J. Am. Chem. Soc. 1996, 118, 3055; Kenner, G. W., McDermott, J. R., Sheppard, R. C. J. Chem. Soc., Chem. Commun. 1971, 636.) in the preparation of 1,4-benzodiazepine-2,5-dione derivatives of general formulae (I), (VI) and (VII), diketopiperazine derivatives of general formula (II), ketopiperazine derivatives and dihydroquinoxalinone derivatives of general formula (III) and (VIII), dihydroimidazole or imidazoline derivatives of general formula (IV), and lactam derivatives of general formula (V). ##STR8##

Brief Summary Text (220):
The pharmaceutical compositions can be administered in a suitable formulation to humans and animals by topical or systemic administration, including oral, inhalational, rectal, nasal, buccal, sublingual, vaginal, parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), intracisternal and intraperitoneal. It will be appreciated that the preferred route may vary with, for example, the condition of the recipient.

Detailed Description Text (16):
Equal amounts (0.1 ml) of 0.1 M solutions of the four appropriate components compound of formulae (XXII), (XV), (XVI) and (IXb), are employed generating a theoretical 10 .mu.mol of final diketopiperazine product (II) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65.degree. C. (using a SAVANT.RTM. evaporator for 2 hours). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and a 5% solution of diethylamine in dichloroethane [Note: 10-15 mg of N,N-(diisopropyl)amino-methylpolustyrene(PS-DIEA) is an excellent resin bound alternative to diethylamine]. Solvents are then evaporated at 65.degree. C. to afford

the cyclized products of formula(II).

Detailed Description Text (47):
General Solution Phase Synthesis of Diketopiperazine Compounds of Formula (VI) via the `3-step, One Pot` Procedure, Employing the Ugi Multi-component Reaction

Detailed Description Text (48):
Equal amounts (0.1 ml) of 0.1 M solutions of the four appropriate components compound of formulae (XIV), (XXXVII), (XVI) and (IX), are employed generating a theoretical 10 .mu.mol of final 1 Diketopiperazine product (VI) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65.degree. C. (using a SAVANT.RTM. evaporator for 2 hours). The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and heat, to afford the cyclized products. Examples of products (examples 96 to 112) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A% and UV A%. Lc/ms analysis is performed using a C18 Hypersil BDS 3 m 4.6.times.50 mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H.sub.2 O/CH.sub.3 CN 10% to 100% 5 min, at a rate of 1 ml/min (Examples 96 to 99), or a mobile phase 5 mM NH.sub.4 OAC.H.sub.2 O/CH.sub.3 CN 10% to 100% 5 min, at a rate of 1 ml/min (Examples 100 to 112). HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+1).

Detailed Description Text (75):
Equal amounts (0.1 ml) of 0.1M solutions of the four appropriate components, ethyl glyoxalate (XXXVII), an isonitrile of formula (XVI), an amine (XVI) and di-BOC protected N-mono-BOC arginine (XIV), are employed generating a theoretical 10 .mu.mol of final diketopiperazine product (VI) for 100% conversion. The 4-component condensation is performed in methanol at room temperature and the solvent evaporated at 65.degree. C. (using a SAVANT.RTM. evaporator for 2 hours) The deprotection/cyclization steps are performed using either a 10% solution of acetyl chloride in methanol, or a 10% solution of trifluoroacetic acid in dichloroethane, and heat, to afford the cyclized products. Examples of products (examples 140 to 160) synthesized using this general methodology are indicated below and purities are determined by lc/ms (liquid chromatography/mass spectrometry) ELSD (evaporative light scattering detector) A%. Lc/ms (liquid chromatography/mass spectrometry) analysis is performed using a C18 Hypersil BDS 3 m 4.6.times.50 mm column (UV 220 nm) with a mobile phase 0.1% TFA IN H.sub.2 O/CH.sub.3 CN 10% to 100% 5 min, at a rate of 1 ml/min. HPLC is interfaced with APCI techniques (Atmospheric Pressure Chemical Ionization). Desired products are seen as (M+1).

PALM INTRANET

Day : Friday
Date: 3/7/2003
Time: 08:07:58

Inventor Name Search Result

Your Search was:

Last Name = STEINER
First Name = SOLOMON

Application#	Patent#	Status	Date Filed	Title	Inventor Name
07883562	Not Issued	166	05/15/1992	DELIVERY SYSTEMS FOR PHARMACOLOGICAL AGENTS ENCAPSULATED WITH PROTEINOIDS	STEINER , SOLOMON
08252979	RE35862	150	06/02/1994	DELIVERY SYSTEMS FOR PHARMACOLOGICAL AGENTS ENCAPSULATED WITH PROTEINOIDS	STEINER , SOLOMON
07510936	5197490	150	04/19/1990	INFORMATION PROCESSING SYSTEM FOR COUNTING COUGHS OR EVALUATING OTHER ACTIVITIES OF A PATIENT	STEINER , SOLOMON S.
08095938	Not Issued	161	07/22/1993	CDNA PHOTOFLUOR PROBE AND METHODS OF MAKING, ASSAYING AND USING SAME	STEINER , SOLOMON S.
06897361	Not Issued	168	08/18/1986	DELIVERY SYSTEMS FOR PHARMACOLOGICAL AGENTS	STEINER , SOLOMON S.
07849186	5352461	150	03/11/1992	SELF ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	STEINER , SOLOMON S.
08441378	6428771	150	05/15/1995	METHOD FOR DRUG DELIVERY TO THE PULMONARY SYSTEM	STEINER , SOLOMON S.
07098027	4925673	250	09/08/1987	DELIVERY SYSTEMS FOR PHARMACOLOGICAL AGENTS ENCAPSULATED WITH PROTEINOIDOS	STEINER , SOLOMON S.
07315440	4976968	150	02/24/1989	ANHYDROUS DELIVERY SYSTEMS FOR PHARMACOLOGICAL AGENTS	STEINER , SOLOMON S.
08299842	5503852	150	09/01/1994	METHOD FOR MAKING SELF-ASSEMBLING DIKETOPIPERAZINE DRUG DELIVERY SYSTEM	STEINER , SOLOMON S.

07177498	4895725	250	04/04/1988	MICROENCAPSULATION OF FISH OIL	STEINER , SOLOMON S.
60145464	Not Issued	159	07/23/1999	UNIT DOSE CAPSULES AND DRY POWDER INHALERS FOR PULMONARY AND NASAL DELIVERY APPLICATIONS	STEINER , SOLOMON S.
60141433	Not Issued	159	06/29/1999	PURIFICATION AND STABILIZATION OF PEPTIDE AND PROTEIN PHARMACEUTICAL AGENTS	STEINER , SOLOMON S.
60127699	Not Issued	159	04/05/1999	METHODS FOR FINE POWDER FORMATION	STEINER , SOLOMON S.
08847352	6071497	150	04/24/1997	METHOD FOR DRUG DELIVERY TO THE PULMONARY SYSTEM	STEINER , SOLOMON S.
60176853	Not Issued	159	01/19/2000	MULTI-SPIKE RELEASE FORMULATION FOR DRUG DELIVERY	STEINER , SOLOMON S.
60176845	Not Issued	159	01/19/2000	DRY POWDER FORMULATIONS OF ANTIHISTAMINE FOR NASAL ADMINISTRATION	STEINER , SOLOMON S.
60023000	Not Issued	159	08/02/1996	AUTOMATED LIPOPHILICITY AND STABILITY ASSAYS FOR DRUG SCREENING	STEINER , SOLOMON S.
08207011	Not Issued	161	03/04/1994	CDNA-PHOTOFLUOR-PROBE AND METHODS OF MAKING, ASSAYING AND USING SAME	STEINER , SOLOMON S.
07315393	4983402	250	02/24/1989	ORALLY ADMINISTERABLE ANF	STEINER , SOLOMON S.
09621092	Not Issued	071	07/21/2000	UNIT DOSE CAPSULES FOR USE IN A DRY POWDER INHALER	STEINER, SOLOMON S.
09606468	6444226	150	06/29/2000	PURIFICATION AND STABILIZATION OF PEPTIDE AND PROTEIN PHARMACEUTICAL AGENTS	STEINER, SOLOMON S.
60349628	Not Issued	020	01/18/2002	COMPOSITIONS FOR TREATMENT OR PREVENTION OF BIOTERRORISM	STEINER, SOLOMON S.
09766362	Not Issued	071	01/19/2001	DRY POWDER FORMULATIONS OF ANTIHISTAMINE FOR NASAL ADMINISTRATION	STEINER, SOLOMON S.
60400159	Not Issued	020	08/01/2002	MODULATION OF IMMUNE RESPONSE	STEINER, SOLOMON S.
10224676	Not Issued	030	08/20/2002	METHODS FOR FINE POWDER FORMATION	STEINER, SOLOMON S.
60406525	Not Issued	020	08/28/2002	MODULATION OF IMMUNE	STEINER,

				RESPONSE	SOLOMON S.
60366302	Not Issued	020	03/20/2002	INHALATION APPARATUS	STEINER, SOLOMON S.
10224761	Not Issued	041	08/20/2002	PURIFICATION AND STABILIZATION OF PEPTIDE AND PROTEIN PHARMACEUTICAL AGENTS	STEINER, SOLOMON S.
10211215	Not Issued	041	08/02/2002	METHOD FOR DRUG DELIVERY TO THE PULMONARY SYSTEM	STEINER, SOLOMON S.
09766394	Not Issued	094	01/19/2001	MULTI-SPIKE RELEASE FORMULATION FOR ORAL DRUG DELIVERY	STEINER, SOLOMON S.
60206123	Not Issued	159	05/22/2000	UNIT DOSE CAPSULES AND DRY POWDER INHALERS FOR PULMONARY AND NASAL DELIVERY APPLICATIONS	STEINER, SOLOMON S.
09543309	6440463	150	04/05/2000	METHODS FOR FINE POWDER FORMATION	STEINER, SOLOMON S.

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name steiner **First Name** solomon

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Friday
Date: 3/7/2003
Time: 08:10:07

Inventor Name Search Result

Your Search was:

Last Name = WILSON
First Name = BRYAN

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08365790	6148883	150	09/21/1994	WOOD TRIM SYSTEM	WILSON , BRYAN A.
07855587	5348066	150	03/23/1992	WOOD TRIM SYSTEM	WILSON , BRYAN A.
09117671	6148584	150	07/31/1998	TRIM ATTACHMENT SYSTEM	WILSON , BRYAN ALEXANDER
60122006	Not Issued	159	03/01/1999	PERMANENT LINER FOR ARTERIES AND OTHER TUBULAR VESSELS	WILSON , BRYAN HADLEY
09351437	Not Issued	161	07/12/1999	MULTI-ARRAY SENSOR AND METHOD OF IDENTIFYING EVENTS USING SAME	WILSON , BRYAN LORRAIN HUMPHREYS
08377667	5712269	150	01/24/1995	M2 RECEPTOR LIGAND FOR THE TREATMENT OF NEUROLOGICAL DISORDERS	WILSON , BRYAN R.
08042872	Not Issued	166	04/05/1993	M2 RECEPTOR LIGAND FOR THE TREATMENT OF NEUROLOGICAL DISORDERS	WILSON , BRYAN R.
08042149	Not Issued	166	04/02/1993	RENIN/ANGIOTENSIN I DIAGNOSTIC ASSAY	WILSON , BRYAN R.
08555359	Not Issued	161	11/08/1995	METHOD FOR FLUORESCENT LABELING OF ANTIBODY	WILSON , BRYAN R.
08383612	Not Issued	161	02/02/1995	RENIN/ANGIOTENSIN I DIAGNOSTIC ASSAY	WILSON , BRYAN R.
60176845	Not Issued	159	01/19/2000	DRY POWDER FORMULATIONS OF ANTIHISTAMINE FOR NASAL ADMINISTRATION	WILSON , BRYAN R.
60406525	Not Issued	020	08/28/2002	MODULATION OF IMMUNE	WILSON, BRYAN

				RESPONSE	
60422399	Not Issued	020	10/29/2002	METHOD FOR SEPARATING AND TRANSFERRING TELEPHONE CALL DATA	WILSON, BRYAN
09661077	Not Issued	093	09/13/2000	WOOD TRIM SYSTEM	WILSON, BRYAN ALEXANDER
09826126	Not Issued	041	04/04/2001	DETECTION OF THERMALLY INDUCED TURBULENCE IN FLUIDS	WILSON, BRYAN LORRAIN HUMPHREYS
09579636	6476859	150	05/26/2000	THERMAL TRACKER	WILSON, BRYAN LORRAIN HUMPHREYS
09447600	6462663	150	11/22/1999	USE OF DETECTOR ARRAYS TO DETECT CESSATION OF MOTION	WILSON, BRYAN LORRAIN HUMPHREYS
09766362	Not Issued	071	01/19/2001	DRY POWDER FORMULATIONS OF ANTIHISTAMINE FOR NASAL ADMINISTRATION	WILSON, BRYAN R.

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name wilson **First Name** bryan

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

PALM INTRANET

Day : Friday
Date: 3/7/2003
Time: 09:36:49

Inventor Name Search Result

Your Search was:

Last Name = ILLUM
First Name = [Nothing Entered]

Application#	Patent#	Status	Date Filed	Title	Inventor Name
07834296	Not Issued	166	02/18/1992	PHARMACEUTICAL COMPOSITIONS	ILLUM , LISBETH
08374671	5792475	150	04/14/1995	LYMPHATIC DELIVERY COMPOSITION	ILLUM , LISBETH
07842351	Not Issued	161	03/24/1992	SMALL PARTICLE DRUG COMPOSITIONS	ILLUM , LISBETH
08954018	Not Issued	161	02/24/1998	DRUG DELIVERY COMPOSITION FOR ALPHA-ADRENO RECEPTOR BLOCKING AGENTS"	ILLUM , LISBETH
08142844	Not Issued	166	10/25/1993	ENHANCED UPTAKE DRUG DELIVERY SYSTEM HAVING MICROSPHERES CONTAINING AN ACTIVE DRUG AND A BIOAVAILABILITY IMPROVING MATERIAL	ILLUM , LISBETH
07865855	Not Issued	166	04/09/1992	ENHANCED UPTAKE DRUG DELIVERY SYSTEM	ILLUM , LISBETH
09214527	Not Issued	161	04/07/1999	COMPOSITION FOR ENHANCED UPTAKE OF POLAR DRUGS FROM MUCOSAL SURFACES	ILLUM , LISBETH
09214580	Not Issued	041	03/30/1999	GENE THERAPY DELIVERY SYSTEM FOR TARGETING TO ENDOTHELIA	ILLUM , LISBETH
07743328	Not Issued	166	08/20/1991	DRUG DELIVERY COMPOSITIONS	ILLUM , LISBETH
08553401	5935604	150	07/01/1996	NASAL DRUG DELIVERY COMPOSITION CONTAINING NICOTINE	ILLUM , LISBETH
08214070	Not Issued	161	03/16/1994	DIAGNOSTIC AID	ILLUM , LISBETH
07956551	Not Issued	166	10/02/1992	ADHESIVE DRUG DELIVERY COMPOSITION	ILLUM , LISBETH

08412094	5690954	150	03/28/1995	ENHANCED UPTAKE DRUG DELIVERY SYSTEM HAVING MICROSPHERES CONTAINING AN ACTIVE DRUG AND A BIOAVAILABILITY IMPROVING MATERIAL	ILLUM , LISBETH
08256431	5629011	150	07/12/1994	COMPOSITION FOR NASAL ADMINISTRATION	ILLUM , LISBETH
08234723	6355276	150	04/28/1994	ADHESIVE DRUG DELIVERY COMPOSITION	ILLUM , LISBETH
08167611	5554388	150	12/14/1993	SYSTEMIC DRUG DELIVERY COMPOSITIONS COMPRISING A POLYCATIONI SUBSTANCE	ILLUM , LISBETH
08190022	5648095	150	07/08/1994	PREPARATION OF MICROPARTICLES	ILLUM , LISBETH
07927576	Not Issued	161	08/10/1992	DIAGNOSTIC AID	ILLUM , LISBETH
08260611	5725871	150	06/15/1994	DRUG DELIVERY COMPOSITIONS COMPRISING LYSOPHOSPHOGLYCEROLIPID	ILLUM , LISBETH
07689926	Not Issued	166	07/08/1991	ADHESIVE DRUG DELIVERY COMPOSITION	ILLUM , LISBETH
07094673	4847091	150	09/23/1987	PHARMACEUTICAL COMPOSITION INCLUDING SODIUM CROMOGLYCATE	ILLUM , LISBETH
09011306	6200602	150	03/30/1998	COMPOSITION FOR ENHANCED UPTAKE OF POLAR DRUGS FROM THE COLON	ILLUM , LISBETH
09000039	Not Issued	161	03/30/1998	LIPID VEHICLE DRUG DELIVERY COMPOSITION CONTAINING VITAMIN E	ILLUM , LISBETH
08963432	6054462	150	11/03/1997	INTRANASAL ANTIMIGRAINE COMPOSITIONS	ILLUM , LISBETH
08899976	5863554	150	07/24/1997	ENHANCED UPTAKE DRUG DELIVERY SYSTEM	ILLUM , LISBETH
08809158	5840341	150	04/21/1997	DRUG DELIVERY COMPOSITION CONTAINING CHITOSAN OR DERIVATIVE THEREOF HAVING A DEFINED Z. POTENTIAL	ILLUM , LISBETH
08718529	Not Issued	166	10/08/1996	INTRANASAL ANTIMIGRAINE COMPOSITION	ILLUM , LISBETH
07469443	5204108	150	04/09/1990	TRANSMUCOSAL FORMULATIONS OF LOW MOLECULAR WEIGHT PEPTIDE DRUGS	ILLUM , LISBETH
09096035	Not	161	06/11/1998	DRUG DELIVERY COMPOSITION	ILLUM ,

	Issued			CONTAINING CHITOSAN OR DERIVATIVE THEREOF HAVING A DEFINED Z. POTENTIAL	LISBETH
09094959	5928669	150	06/15/1998	LYMPHATIC DELIVERY COMPOSITION	ILLUM , LISBETH
09088185	6391318	150	06/01/1998	VACCINE COMPOSITIONS FOR INTRANASAL ADMINSTRATION COMPRISING CHITOSAN AND USE THEREOF	ILLUM , LISBETH
08553716	Not Issued	125	01/29/1996	DRUG DELIVERY COMPOSITION FOR ALPHA-ADRENO RECEPTOR BLOCKING AGENTS	ILLUM , LISBETH
07424320	Not Issued	166	11/20/1989	ENHANCED UPTAKE DRUG DELIVERY SYSTEM	ILLUM , LISBETH
09341546	6465626	150	08/18/1999	PHARMACEUTICAL COMPOSITIONS OF CHITOSAN WITH TYPE-A GELATIN	ILLUM , LISBETH
09059646	6387408	150	04/13/1998	ADHESIVE DRUG DELIVERY COMPOSITION	ILLUM , LISBETH
08776470	Not Issued	161	03/28/1997	DRUG DELIVERY COMPOSITION FOR THE NASAL ADMINISTRATION OF ANTIVIRAL AGENTS	ILLUM , LISBETH
07004189	4904479	150	01/15/1987	DRUG DELIVERY SYSTEM	ILLUM , LISBETH
09214561	Not Issued	161	04/07/1999	COMPOSITIONS SUITABLE FOR DELIVERY OF GENES TO EPITHELIAL CELLS	ILLUM , LISBETH
09475680	6310089	150	12/30/1999	COMPOSITION FOR THE ADMINISTRATION OF A D1-AGONISTS	ILLUM, LISBETH
09848600	Not Issued	041	05/03/2001	DRUG DELIVERY COMPOSITION FOR THE NASAL ADMINISTRATION OF ANTIVIRAL AGENTS	ILLUM, LISBETH
09834312	Not Issued	041	04/13/2001	NOVEL FORMULATIONS OF FEXOFENADINE	ILLUM, LISBETH
09521141	Not Issued	161	03/08/2000	CONTROLLED RELEASE MICROSPHERE DELIVERY SYSTEM	ILLUM, LISBETH
09920698	Not Issued	161	01/01/0001	COMPOSITIONS FOR NASAL ADMINISTRATION	ILLUM, LISBETH
09586139	6342251	150	06/02/2000	COMPOSITIONS FOR NASAL ADMINISTRATION	ILLUM, LISBETH
09944291	Not	041	08/31/2001	POLYMER COMPOSITIONS FOR	ILLUM,

	Issued			POLYNUCLEOTIDE DELIVERY	LISBETH
09619400	Not Issued	161	07/19/2000	NOVEL DOSAGE FORM	ILLUM, LISBETH
09692088	6387917	150	10/19/2000	SALTS OF OPIOID ANALGESICS, PARTICULARLY MORPHINE, AND METHODS OF USING SAME	ILLUM, LISBETH
09841228	Not Issued	041	04/24/2001	NASAL DRUG DELIVERY COMPOSITION	ILLUM, LISBETH
10141312	Not Issued	030	05/08/2002	VACCINE COMPOSITIONS INCLUDING CHITOSAN FOR INTRANASAL ADMINISTRATION AND USE THEREOF	ILLUM, LISBETH
10196590	Not Issued	020	07/15/2002	DELIVERY OF DRUGS TO MUCOSAL SURFACES	ILLUM, LISBETH

Search and Display More Records.

Search Another: Inventor

Last Name illum **First Name**

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page